Jundishapur Journal of Microbiology

Published by: Kowsar

Construction of a DNA Vaccine Encoding Mtb32C and HBHA Genes of Mycobacterium tuberculosis

Roghayeh Teimourpour 1 , Ali Sadeghian 1 , Zahra Meshkat 1 , * , Majid Esmaelizad 2 , Mojtaba Sankian 3 and Ahmad-Reza Jabbari 2
Authors Information
1 Department of Microbiology and Virology, Antimicrobial Resistance Research Center, Bu Ali Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Genomics and Genetic Engineering Department, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
3 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Jundishapur Journal of Microbiology: August 01, 2015, 8 (8); e21556
  • Published Online: August 29, 2015
  • Article Type: Research Article
  • Received: June 27, 2014
  • Revised: September 14, 2014
  • Accepted: October 1, 2014
  • DOI: 10.5812/jjm.21556

To Cite: Teimourpour R, Sadeghian A, Meshkat Z, Esmaelizad M, Sankian M, et al. Construction of a DNA Vaccine Encoding Mtb32C and HBHA Genes of Mycobacterium tuberculosis, Jundishapur J Microbiol. 2015 ; 8(8):e21556. doi: 10.5812/jjm.21556.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sato K, Tomioka H, Shimizu T, Gonda T, Ota F, Sano C. Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J Infect Dis. 2002; 185(8): 1139-47[DOI][PubMed]
  • 2. Blaser MJ, Dolin R, Bennett JE. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2009;
  • 3. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 2012; 36(3): 514-32[DOI][PubMed]
  • 4. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2010; 90(6): 361-6[DOI][PubMed]
  • 5. Dietrich G, Viret JF, Hess J. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine. 2003; 21(7-8): 667-70[PubMed]
  • 6. Dara M, Dadu A, Kremer K, Zaleskis R, Kluge HH. Epidemiology of tuberculosis in WHO European Region and public health response. Eur Spine J. 2013; 22 Suppl 4: 549-55[DOI][PubMed]
  • 7. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis. 2000; 31 Suppl 3-7[DOI][PubMed]
  • 8. Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries. 2009; 3(1): 5-15[PubMed]
  • 9. Orme IM. Current progress in tuberculosis vaccine development. Vaccine. 2005; 23(17-18): 2105-8[DOI][PubMed]
  • 10. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001; 412(6843): 190-4[DOI][PubMed]
  • 11. Brighenti S, Andersson J. Local immune responses in human tuberculosis: learning from the site of infection. J Infect Dis. 2012; 205 Suppl 2-24[DOI][PubMed]
  • 12. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004; 172(12): 7618-28[PubMed]
  • 13. Ribeiro-Guimaraes ML, Pessolani MC. Comparative genomics of mycobacterial proteases. Microb Pathog. 2007; 43(5-6): 173-8[DOI][PubMed]
  • 14. Ribeiro-Guimaraes ML, Tempone AJ, Amaral JJ, Nery JA, Gomes Antunes SL, Pessolani MC. Expression analysis of proteases of Mycobacterium leprae in human skin lesions. Microb Pathog. 2007; 43(5-6): 249-54[DOI][PubMed]
  • 15. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a Laboratory Manual. 2001; 2
  • 16. Jordan M, Wurm F. Transfection of adherent and suspended cells by calcium phosphate. Methods. 2004; 33(2): 136-43[DOI][PubMed]
  • 17. WHO . Global tuberculosis report 2013 2013;
  • 18. Shin AR, Lee KS, Lee JS, Kim SY, Song CH, Jung SB, et al. Mycobacterium tuberculosis HBHA protein reacts strongly with the serum immunoglobulin M of tuberculosis patients. Clin Vaccine Immunol. 2006; 13(8): 869-75[DOI][PubMed]
  • 19. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 2012; 8(5)[DOI][PubMed]
  • 20. Parida SK, Kaufmann SH. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol. 2010; 22(3): 374-84[DOI][PubMed]
  • 21. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet. 2002; 32(1): 97-105[DOI][PubMed]
  • 22. van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis. 2004; 4(12): 739-49[DOI][PubMed]
  • 23. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozzi FD, et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis. 2002; 185(4): 513-20[DOI][PubMed]
  • 24. Pethe K, Aumercier M, Fort E, Gatot C, Locht C, Menozzi FD. Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J Biol Chem. 2000; 275(19): 14273-80[PubMed]
  • 25. Vidal Pessolani MC, Marques MA, Reddy VM, Locht C, Menozzi FD. Systemic dissemination in tuberculosis and leprosy: do mycobacterial adhesins play a role? Microbes Infect. 2003; 5(7): 677-84[PubMed]
  • 26. Guerrero GG, Debrie AS, Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine. 2010; 28(27): 4340-7[DOI][PubMed]
  • 27. Rouanet C, Debrie AS, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect. 2009; 11(13): 995-1001[DOI][PubMed]
  • 28. Guerrero GG, Locht C. Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection. Clin Dev Immunol. 2011; 2011: 730702[DOI][PubMed]
  • 29. Irwin SM, Izzo AA, Dow SW, Skeiky YA, Reed SG, Alderson MR, et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun. 2005; 73(9): 5809-16[DOI][PubMed]
  • 30. Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun. 1999; 67(8): 3998-4007[PubMed]
  • 31. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun. 2004; 72(11): 6622-32[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments